The label may promise billions of CFU. The harder question is how many are still functionally alive after drying injury, storage, stomach acid, bile, and the food or drink you take them with.
This report follows the bacteria step by step: from raw freeze-dry survival, through active-cell loss, harsh processing injury, storage decay, and simulated gastrointestinal stress. Speculative VBNC / mid-active “revival” claims are listed separately and excluded from the final calculation when they lack quantified human-GI proof.
Raw post-freeze-dry CFU survival is not the same as effective gut-delivered probiotic survival. It may only show that cells were culturable under lab recovery conditions. It does not prove membrane fitness, metabolic activity, acid tolerance, bile tolerance, adhesion, immediate gut function, or survival after storage.
In this report, raw ≥90% freeze-dry survival is disqualified from the final effective-survival calculation unless the same finished product also proves active-cell fraction, metabolic function, realistic acid/bile/INFOGEST survival, and shelf-life performance.
Imagine 100 units of starting reference dose. How many remain after each evidence-based discount? The journey below separates fresh use, 12-month storage, harsh processing, and the L. reuteri DSM 17938 process example.
Rows 5, 6, and 7 are the highlighted GI-stress outcomes. They are the concluded values for probiotics entering the gut with different media: water, juice, or porridge/food matrix.
| Process identified | Formula / source value | Fresh ordinary freeze-dried + water | Fresh ordinary freeze-dried + juice | Fresh ordinary freeze-dried + porridge | 12-month storage overlay: ordinary branch, CFU at 5°C / 25°C | 12-month storage overlay: AFU upper-bound at 30°C / 40°C | Harsh coated/dried branch | L. reuteri DSM 17938 oxygen-cultivated | L. reuteri DSM 17938 N₂-cultivated |
|---|---|---|---|---|---|---|---|---|---|
| 0. Starting reference | Start = 100% | 100% post-FD measured / labelled dose | 100% post-FD measured / labelled dose | 100% post-FD measured / labelled dose | 100% post-FD measured / labelled dose, then apply storage multiplier | 100% post-FD measured / labelled dose, then apply AFU upper-bound multiplier | 100% before harsh dried/coated stress | 100% pre-FD reference | 100% pre-FD reference |
| 1. Raw freeze-dry CFU survival | R_FD = post-FD CFU ÷ pre-FD CFU | Not measured in INFOGEST; do not invent | Not measured | Not measured | Not measured in the INFOGEST products; storage overlay applied downstream only | AFU values are not raw freeze-dry CFU survival | Not measured as freeze-dry CFU survival; IFC harsh branch used instead | 61.8% ± 2.4% | 11.5% ± 4.3% |
| 2. Functional-fitness discount | F_active = 34.77% Average active fraction from dried IFC samples: 36.31%, 33.23%, 34.78%. |
100 × 34.77% = 34.77% before GI | 34.77% before GI | 34.77% before GI | 5°C CFU: 34.77 × 76.9% = 26.73% 25°C CFU: 34.77 × 61.5% = 21.39% |
30°C AFU upper-bound: 34.77 × 67.0% = 23.30% 40°C AFU upper-bound: 34.77 × 29.7% = 10.33% |
Do not use 34.77%; harsh process has its own worse active fraction | 61.8 × 34.77% = 21.49% before GI | 11.5 × 34.77% = 4.00% before GI |
| 3. Harsher coated/dried processing | Mortality average = 83.55%; non-dead = 16.45%; strict active = 0.58% | N/A | N/A | N/A | N/A | N/A | Loose non-dead gate: 16.45% Strict active gate: 0.58% |
N/A | N/A |
| GI-STRESS OUTCOMES — rows 5, 6, and 7 are the concluded values after active-cell / storage / harsh-process discounting, depending on intake medium. | |||||||||
| 5. GI-stress survival: water | 10^-1.6 = 2.51% | 34.77 × 2.51% = 0.873% | N/A | N/A | 5°C CFU: 0.672% 25°C CFU: 0.537% |
30°C AFU upper-bound: 0.585% 40°C AFU upper-bound: 0.259% |
Loose: 0.413% Strict active: 0.0146% |
0.540% | 0.100% |
| 6. GI-stress survival: juice | 10^-2.5 = 0.316% | N/A | 34.77 × 0.316% = 0.110% | N/A | 5°C CFU: 0.0846% 25°C CFU: 0.0676% |
30°C AFU upper-bound: 0.0737% 40°C AFU upper-bound: 0.0327% |
Loose: 0.0520% Strict active: 0.00183% |
0.0680% | 0.0126% |
| 7. GI-stress survival: porridge / food matrix | 10^-1.2 = 6.31% | N/A | N/A | 34.77 × 6.31% = 2.19% | 5°C CFU: 1.69% 25°C CFU: 1.35% |
30°C AFU upper-bound: 1.47% 40°C AFU upper-bound: 0.652% |
Loose: 1.04% Strict active: 0.0366% |
1.36% | 0.252% |
| 8. Final realistic classification | Active-discounted + storage or process branch + GI-stressed fraction | ~0.87% | ~0.11% | ~2.19% | 12-month CFU overlay: ~0.068–1.69% depending on temperature and medium | AFU-only upper-bound overlay: ~0.033–1.47%; not accepted as full functional equivalence | Strict active harsh: ~0.0018–0.0366% Loose non-dead: ~0.052–1.04% |
~0.068–1.36% using generic active discount | ~0.013–0.252% using generic active discount |
The arithmetic is deliberately strict. A bacterium is not credited as an immediate functional gut-delivered probiotic just because it is not visibly dead or because it might revive later in a generous laboratory recovery window.
| Symbol | Meaning | Value used | Basis / limitation |
|---|---|---|---|
| R_FD | Raw freeze-dry CFU survival | Study-specific; not invented where absent | Where not reported, downstream calculation starts from measured / labelled post-FD dose. This is not proof of 100% freeze-dry survival. |
| F_active | Functional-fitness discount from dried imaging-flow-cytometry samples | (36.31 + 33.23 + 34.78) / 3 = 34.77% | Used as an active-cell drying-stress surrogate. It is not a universal law for every product. |
| H_dead | Harsh coated/dried mortality | (73.53 + 87.05 + 90.06) / 3 = 83.55% | Used only for the harsh-processing branch. |
| H_non_dead | Harsh coated/dried non-dead remainder | 100 − 83.55 = 16.45% | Loose and generous, because non-dead still includes impaired cells. |
| H_active | Harsh coated/dried strict active fraction | (0.99 + 0.43 + 0.32) / 3 = 0.58% | Stricter and more relevant to immediate function. |
| GI_water | INFOGEST water / empty-stomach-like loss | 10^-1.6 = 2.51% | Converted from average 1.6 log10 CFU decrease. |
| GI_juice | INFOGEST juice loss | 10^-2.5 = 0.316% | Converted from average 2.5 log10 CFU decrease. |
| GI_porridge | INFOGEST porridge / food-matrix loss | 10^-1.2 = 6.31% | Converted from average 1.2 log10 CFU decrease. |
After the active-cell and GI-stress discounts are applied, the popular impression that freeze-dried probiotics commonly deliver 8–20%+ functional cells to the gut is not supported by this evidence chain.
| Category | Corrected evidence-weighted effective survival | Reason | Earlier unsupported / withdrawn wording |
|---|---|---|---|
| Harsh / poorly processed / unverified | Near-zero to ~1%; strict active-only harsh cases can be <0.05% | Coated/dried strict active fraction ~0.58%, then GI log-loss conversion. | Near-zero to ~0.5% was directionally close but too narrow for loose non-dead counting. |
| Ordinary fresh non-spore freeze-dried, no product-specific proof | ~0.1% to ~2.2% | 34.77% active fraction × INFOGEST juice/water/porridge direct CFU survival. | ~0.1% to 5% was too high under this evidence chain. |
| Ordinary after 12 months at acceptable 5–25°C using PDS-style CFU overlay | ~0.07% to ~1.7%, depending on intake matrix | Stored CFU multiplier applied before GI stress. AFU-only values are kept as upper-bound, not functional equivalence. | Any claim that storage does not matter is rejected. |
| Food-assisted / better matrix but no product-specific active proof | ~2% range, not automatically 3–10% | Porridge improves GI survival but does not erase active-cell discount. | 3–10% withdrawn unless product-specific data proves better active fraction and lower GI loss. |
| Best engineered / protected product | Not generically assignable | Needs same-product proof: CFU + IFC active fraction + metabolic assay + acid/bile/INFOGEST + shelf-life data. | 8–20%+ withdrawn as a general category. |
This section separates measured evidence from promotional-sounding or hypothesis-level narration. These claims are not credited into the survival calculation unless they come with quantified, relevant parameters.
| Claim / statement type | Source URL | What is supported | What is missing | Decision for calculation |
|---|---|---|---|---|
| “VBNC cells exist in lyophilized probiotic preparations.” | FFHD, Blinkova et al. 2014 | Reasonable; the paper measured VBNC fractions in commercial lyophilized preparations. | No direct human GI recovery test. | Use only to show CFU can undercount membrane-intact/nonculturable cells. |
| “VBNC cells may have potential to return to active growth.” | FFHD, Blinkova et al. 2014 | Plausible microbiology hypothesis. | No quantified human-GI pH, bile, enzyme, transit-time, mucus, microbiome, nutrient, or recovery-window proof. | Excluded from immediate functional gut-survival. |
| “Expired probiotics may retain high potential medical effect.” | FFHD, Blinkova et al. 2014 | Some cells may remain membrane-intact / VBNC. | No clinical endpoint, no product-specific efficacy, no proof that membrane-intact equals therapeutic effect. | Downgraded as overstated and not evidence-based for effectiveness. |
| “Once in intestines, these forms can start developing.” | FFHD, Blinkova et al. 2014 | Speculative possibility. | No controlled realistic gut experiment proving rapid recovery during transit. | Excluded as speculative narration. |
| “Favourable conditions” for VBNC revival | FFHD, Blinkova et al. 2014 | Generic phrase only. | No operational definition: pH profile, bile concentration, enzyme exposure, transit time, oxygen gradient, mucus contact, microbiome competition, or recovery time. | Not usable as a calculation parameter. |
| 72-hour saline / laboratory recovery observations | FFHD, Blinkova et al. 2014 | Can show laboratory resuscitation-like behaviour under favourable conditions. | 72 hours in saline + plating is not realistic immediate GI function. | Excluded from human-realistic gut-delivery calculation. |
| Sorted-cell growth after 48/72 h | Kiepś et al., 2023 | Useful proof that active, mid-active, and dead gates behave differently. | Delayed laboratory growth recovery is not immediate in-vivo gut function. | Kept as biological support; not used as a multiplier. |
| “AFU stayed high, therefore functional survival stayed high.” | Visciglia et al., 2022 | AFU/membrane integrity may persist longer than CFU. | AFU is not equivalent to culturable, metabolically effective, acid/bile-tolerant probiotic function. | Used only as upper-bound caution, not full credit. |
| “Raw >90% freeze-dry survival proves effective probiotic delivery.” | General literature / product-marketing style claim | Some optimized processes can report high raw CFU survival. | No active-cell, metabolic, acid/bile, adhesion, storage, or realistic GI proof. | Disqualified unless same finished product proves downstream function. |
| “Reported survival-rate percentages can replace direct log-loss conversion.” | Treven et al., 2024 | The paper reports average log decreases and survival-rate metrics. | For delivered-cell arithmetic, direct CFU survival is calculated as 10^(-log loss). | Use log-loss conversion for this model. |
| Evidence item | Source URL | How it is used | Limits |
|---|---|---|---|
| Dried samples active fractions 36.31%, 33.23%, 34.78%; mid-active II 41.77%, 44.61%, 39.45%; dead 6.49%, 10.42%, 9.22% | Kiepś et al., 2023, imaging-flow-cytometry paper | Active-cell discount for dried-cell injury. | Dried / coated samples are not all freeze-dried; used as drying-stress surrogate, not as universal product proof. |
| Coated samples dead 73.53%, 87.05%, 90.06%; active cells ≤1% | Kiepś et al., 2023 | Harsh-processing branch. | Not a consumer-product survival proof. |
| PDS-08 plate count vs flow cytometry; CFU decays faster than AFU; possible VBNC shift | Visciglia et al., 2022 | Storage overlay and CFU ≠ AFU caution. | Different product; not directly combined in the same experiment with the INFOGEST table. |
| PDS-08 storage after 12 months: CFU 76.9% at 5°C, 61.5% at 25°C; AFU 86.3%, 93.8%, 67.0%, 29.7% at 5/25/30/40°C; D1 49.2 vs 677.2 months at 25°C | Visciglia et al., 2022 | Storage multiplier and AFU upper-bound caution. | AFU is not accepted as full functional equivalence. |
| INFOGEST commercial products: average 1.6 log CFU loss with water, 2.5 log with juice, 1.2 log with porridge; pH/enzymes/bile in standardized digestion model | Treven et al., 2024 | GI-stress survival conversion. | In vitro static digestion, not human clinical transit. |
| L. reuteri DSM 17938: 61.8% ± 2.4% freeze-dry survival with oxygen vs 11.5% ± 4.3% with nitrogen; bile tolerance improved, acid tolerance reduced | Rao et al., 2023 | Strain / process-dependence example. | Not proof that oxygen-cultivated cells achieve high effective gut delivery after generic active discount. |
| VBNC in lyophilized probiotic preparations; 4.1–99.7% in E. coli preparations, 58.8–80.4% in non-expired lactobacilli | Blinkova et al., 2014, FFHD | Evidence that VBNC fractions can exist. | Gut-revival / medical-effect claims are not used as evidence. |
| Probiotics definition, strain specificity, adequate amounts, CFU at expiration, and warning that not all labelled probiotics have proven benefits | NIH Office of Dietary Supplements fact sheet | Regulatory/clinical framing and strain-specific caution. | Does not provide freeze-dried functional survival rates. |
This report is a research-style technical analysis. It is not medical diagnosis, treatment advice, or a recommendation to start, stop, or substitute any therapy. Immunocompromised, critically ill, premature-infant, catheterized, central-line, or severe-gut-disease cases require clinician review.
No disclaimer can guarantee that no person will sue. This document is drafted to reduce overclaiming by separating evidence from speculation, but it is not legal advice and should be reviewed by qualified counsel before publication, advertising, regulatory submission, or litigation use.
The calculations do not certify, endorse, or condemn any named consumer product. They combine results from different studies to build evidence-weighted scenarios. A product-specific claim requires finished-product testing under the exact strain mix, formulation, capsule, packaging, expiry, storage condition, and instructions for use.
INFOGEST and other simulated digestion tests are useful controls, but they are not human clinical endpoint studies. They do not prove colonization, symptom benefit, immune effect, microbiome correction, disease treatment, or disease prevention.
Multiplying R_FD, active-cell fraction, storage, and GI survival from separate studies is a scenario estimate, not a statistical meta-analysis. Confidence intervals, causal certainty, and product rankings cannot be validly inferred from the table.
VBNC and mid-active cells are excluded from immediate functional survival because no cited evidence proves reliable rapid recovery under quantified realistic human GI conditions. Laboratory recovery after 48/72 hours is not counted as human-realistic immediate gut delivery.
This report should not be used to claim that a particular probiotic works, fails, treats disease, or delivers a specific health outcome. It is a calculation framework and evidence critique, not consumer advertising copy.
Displayed percentages are rounded for readability. The conclusions depend on the specific input studies and assumptions stated here. Different strains, enteric coatings, foods, storage environments, or validated manufacturing conditions may produce different results.